| Literature DB >> 34907270 |
Gabriel Kai Yang Tan1, Christoph Sheng Chong1, Hamid Rahmatullah Bin Abd Razak2,3.
Abstract
Although both long and short cephalomedullary devices (CMDs) are used in the treatment of extracapsular hip fractures, the advantages of either option are subject to debate. This study aims to evaluate the differences in clinical outcomes with long versus short CMDs for extracapsular hip fractures. Studies included must have included subjects with at least 1 year of follow-up and reported on at least one of the following outcomes: rate of reoperation; rate of peri-implant fracture; operating time; blood loss; complication rate; length of hospital stay; 1-year mortality. Only articles written in the English language were included in this study. A search was conducted across the databases of Medline, Embase, CENTRAL (Cochrane Central Register of Controlled Trials), CINAHL and Scopus for articles published from the inception of the database to 1 November 2020. Included studies were assessed for their risk of bias using the Risk of Bias Tool (RoB2) and the risk-of-bias in non-randomized studies - of interventions (ROBINS-I) tool. A total of 8460 fractures from 16 studies were included in the analysis, with 3690 fixed with short, and 4770 fixed with long CMDs. A meta-analysis of the results revealed that short CMDs offer peri-operative advantages, while long CMDs could offer longer-term advantages. Limitations of this study include a lack of randomized control trials included in the analysis. In conclusion, when planning for the treatment of extracapsular hip fractures, a patient specific approach may be necessary to make a decision according to the individual risk profile of the patient.Entities:
Mesh:
Year: 2021 PMID: 34907270 PMCID: PMC8671534 DOI: 10.1038/s41598-021-03210-1
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Eligibility criteria.
Figure 2Flowchart of studies in review.
Eligible studies, study characteristics, population demographics.
| S/N | Study | Country | Inclusion period | Study design | Device model (short/long) | Number of fractures | Sample size (short/long) | Gender (M/F) | Mean age/years (SD) | Length of F/u (months) | ASA score (1/2/3/4) | OTA classification (31A1/2/3) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Hulet et al.[ | USA | 2000–2012 | Retrospective cohort | NI | 201 | 70 | 131 | Short 23/47 Long 57/74 ( | Short 70.6 (19.1) Long 70.1 (17.4) ( | 40.6 (range 6–158) | NI | Short 23/28/19 Long 19/57/55 ( |
| 2 | Krigbaum et al.[ | USA | 2001–2010 | Retrospective cohort | NI | 262 | 125 | 137 | Short 120/5 ( | ( | Long 33.6 (SD 31.2) Short 24 (SD 26.4) | NI | Short 0/125/0 |
| 3 | Kleweno et al.[ | USA | 2004–2010 | Retrospective cohort | Gamma 3, Synthes TFNA/Gamma 2, Gamma 3, Synthes TFNA | 559 | 219 | 340 | NI | NI | 30.1 (range 12–85) | NI | NI |
| 4 | Hou et al.[ | China | 2005–2009 | Retrospective cohort | TFNA (170 mm)/TFNA | 283 | 100 | 183 | Short 16/84 Long 57/126 ( | Short 81.0 (range 53–102) Long 78.6 (range 47–98) ( | 37 (SD 2.3) | Short 0/11/64/14 (NI = 11) Long 1/24/101/32 (NI = 25) | Short 59/41/0 Long 67/116/0 ( |
| 5 | Frisch et al.[ | USA | 2005–2010 | Retrospective cohort | InterTAN/InterTAN | 169 | 72 | 97 | Short 18/54 Long 30/67 ( | Short 76.2 (12.3) Long 76.3 (15.2) ( | NC | NI | NI |
| 6 | Vaughn et al.[ | USA | 2006–2011 | Retrospective cohort | Gamma 3/Gamma 3 | 256 | 60 | 196 | NI | NI | > 12 | NI | Short 37/23/0 Long 106/90/0 |
| 7 | Boone et al.[ | USA | 2008–2011 | Retrospective cohort | Gamma 3/Gamma 3 | 201 | 82 | 119 | Short 25/57 Long 32/87 ( | Short 83.3 (8.0) Long 79.6 (9.6) ( | NC | NI | Short 31/51/0 Long 28/91/0 ( |
| 8 | Guo et al.[ | China | 2008–2013 | Retrospective cohort | Gamma 3 (180 mm)/Gamma 3 (320, 340, 360 mm) | 178 | 102 | 76 | Short 42/60 Long 43/33 ( | Short 82.7 (9.9) Long 78.9 (8.8) ( | 23.1 (SD 6.8) | NI | Short 47/55/0 Long 26/50/0 ( |
| 9 | Sellan et al.[ | Canada | 2008–2013 | RCT | InterTAN (180–200 mm)/InterTAN (260–460 mm) | 108 | 71 | 37 | Short 20/51 Long 14/23 ( | Short 80.6 (0.9) Long 78.0 (1.7) ( | > 12 | NI | All A1/A2 |
| 10 | Okcu et al.[ | Turkey | 2009 | RCT | PFNA (240 mm)/PFNA (340–420 mm) | 33 | 15 | 18 | Short 4/11 Long 4/14 ( | Short 78 (range 67–95) Long 81 (range 73–89) ( | Short 14.0 (range 12–19) Long 14.5 (range 12–21) | NI | Short 0/0/15 Long 0/0/18 |
| 11 | Hong et al.[ | Singapore | 2009–2012 | Retrospective cohort | PFNA (200 mm)/PFNA (320, 340, 380 mm) | 64 | 44 | 20 | Short 13/31 Long 6/14 ( | Short 80.0 (range 60–93) Long 79.8 (range 56–97) ( | > 12 | Short 1/22/21/0 Long 1/9/10/0 ( | Short 11/33/0 Long 4/16/0 ( |
| 12 | Sadeghi et al.[ | USA | 2009–2014 | Retrospective cohort | Gamma 3 (170–180 mm), TFNA (170–180 mm)/Gamma 3, TFNA | 5526 | 2418 | 3108 | Short 720/1698 Long 938/2170 | Short 81.2 (10.8) Long 80.6 (11.0) | NC | Short (mean = 2.9) Long (mean = 2.8) ( | NI |
| 13 | Li et al.[ | China | 2010–2012 | Retrospective cohort | PFNA/PFNA | 156 | 97 | 59 | Short 46/51 Long 20/39 ( | Short 76.81 (6.56) Long 74.85 (8.15) ( | NC | Short 49/31/18 Long 29/19/11 ( | Short 17/27/15 Long 28/44/25 ( |
| 14 | Raval et al.[ | UK | 2011–2012 | Retrospective cohort | PFNA (240 mm) /PFNA (340–400 mm) | 80 | 40 | 40 | Short 11/29 Long 13/27 ( | Short 77.1 (9.2) Long 76.1 (8.7) ( | > 12 | NI | Short 12/24/4 Long 9/24/7 ( |
| 15 | Bovbjerg et al.[ | Denmark | 2012 | Retrospective cohort | Gamma 3/Gamma 3 | 216 | 95 | 121 | Short 28/67 Long 43/78 ( | Short 83.1 (8.35) Long 82.9 (7.69) ( | > 12 | NI | NI |
| 16 | Shannon et al.[ | USA | 2014–2017 | RCT | Synthes TFNA, Gamma 3, Affixus/ Synthes TFNA, Gamma 3, Affixus | 168 | 80 | 88 | Short 20/60 Long 25/63 ( | Short 82 (range 79–84) Long 79 (range 76–82) ( | Short 10.5 Long 10.2 | NI | Short 13/61/6 Long 12/67/9 ( |
RCT randomized controlled trial, NI no information, NC not possible to calculate.
*Indicates statistically significant difference reported.
All included studies were subject to an assessment of bias, with the revised Cochrane risk-of-bias tool (RoB 2) for the randomized controlled trials, and Risk-of-bias in Non-randomized Studies—of Interventions (ROBINS-I) tool for the retrospective cohort studies[34,35]. The detailed information on the assessment for bias is reported in Tables 2 and 3 respectively. None of the studies received external funding.
Intra-operative results.
| Study | Mean operating time/min (SD/range) | Mean est. blood loss/mL (SD/range) | No. of patients requiring transfusion (%) | Length of stay/days (SD/range) | |||||
|---|---|---|---|---|---|---|---|---|---|
| Hulet et al.[ | Short | NI | NI | NI | NI | NI | NI | NI | NI |
| Long | NI | NI | NI | NI | |||||
| Krigbaum et al.[ | Short | 66 (30.00) | < 0.001* | NI | NI | NI | NI | 6.9 (4.8) | 0.018* |
| Long | 90 (48.00) | NI | NI | 9.1 (8.9) | |||||
| Kleweno et al.[ | Short | 51 (22.00) | < 0.00* | NI | NI | NI | NI | NI | NI |
| Long | 70 (35.00) | NI | NI | NI | |||||
| Hou et al.[ | Short | 41 (range 19–106) | < 0.000* | 100 | 0.031* | 42 (42.0%) | 0.462 | 6.4 | 0.383 |
| Long | 61 (range 16–216) | 135 | 83 (45.4%) | 6.8 | |||||
| Frisch et al.[ | Short | 63.8 (20.00) | 0.001* | Long 161.4 (122.40) | 0.002* | NI | NI | NI | NI |
| Long | 82.6 (26.40) | Short 208.1 (116.90) | NI | NI | |||||
| Vaughn et al.[ | Short | NI | NI | NI | NI | NI | NI | NI | NI |
| Long | NI | NI | NI | NI | |||||
| Boone et al.[ | Short | 44.0 (10.70) | < 0.001* | 92.6 (47.20) | 0.002* | 33 (40.2%) | 0.002* | 7.7 (4.10) | 0.393 |
| Long | 56.8 (19.40) | 135.5 (91.90) | 68 (57.1%) | 8.0 (4.50) | |||||
| Guo et al.[ | Short | 43.5 (12.30) | 0.002* | 90.7 (50.60) | 0.004* | 42.3% | 0.041* | 12.9 (6.50) | 0.420 |
| Long | 58.5 (20.30) | 127.8 (85.90) | 56.7% | 12.7 (6.20) | |||||
| Sellan et al.[ | Short | 60 (range 30–120) | 0.021* | NI | NI | 33 (46.4%) | 0.364 | 20.2 (2.80) | 0.345 |
| Long | 73 (range 30–203) | NI | 16 (41.0%) | 15.7 (3.70) | |||||
| Okcu et al.[ | Short | 52.6 (range 34–65) | < 0.001* | NI | NI | NI | NI | 5.4 (range 2–11) | 0.510 |
| Long | 71.8 (range 57–94) | NI | NI | 4.9 (range 2–9) | |||||
| Hong et al.[ | Short | 73 (range 40–121) | 0.617 | NI | NI | NI | NI | 15.5 (range 4–53) | 0.793 |
| Long | 78.2 (range 29–315) | NI | NI | 14.0 (range 3–30) | |||||
| Sadeghi et al.[ | Short | 47.4 (22.80) | NI | 99.8 (105.50) | NI | NI | NI | 5.34 (4.24) | NI |
| Long | 62.7 (33.10) | 135.7 (151.70) | NI | 5.57 (4.43) | |||||
| Li et al.[ | Short | 53.08 (8.51) | 0.000* | 69.95 (21.55) | 0.063 | NI | NI | NI | NI |
| Long | 60.61 (11.43) | 77.97 (31.88) | NI | NI | |||||
| Raval et al.[ | Short | 58.6 (12.60) | 0.016* | Long 172.7 (156.90) | 0.042* | 4 (10.0%) | 0.210 | 11.1 (6.20) | 0.937 |
| Long | 87.7 (32.60) | Short 341.7 (191.80) | 8 (20.0%) | 10.9 (4.80) | |||||
| Bovbjerg et al.[ | Short | NI | NI | NI | NI | NI | NI | NI | NI |
| Long | NI | NI | NI | NI | |||||
| Shannon et al.[ | Short | 51 (range 48–55) | < 0.0001* | 70 (range 61–79) | < 0.001* | NI | NI | NI | NI |
| Long | 80 (range 74–87) | 207 (range 185–229) | NI | NI | |||||
NI no information.
*Indicates statistically significant difference reported.
Post-operative results and complications.
| Study | 1-Year post-operative mortality (%) | Overall complication rate (%) | Overall rate of reoperation | Overall rate of peri-prosthetic fractures | Overall rate of peri-prosthetic infections | 1 Year post-operative harris hip score (SD) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hulet et al.[ | Short | 33 (47.14%) | NI | 19 (27.14%) | NI | NI | NI | 0 (0.00%) | NI | NI | NI | NI | NI |
| Long | 41 (31.30%) | 34 (25.95%) | NI | 0 (0.00%) | NI | NI | |||||||
| Krigbaum et al.[ | Short | 35 (28%) | 0.33 | 21.0% | 0.710 | 5.00% | 0.120 | NI | NI | NI | NI | NI | NI |
| Long | 47 (34%) | 19.0% | 1.00% | NI | NI | NI | |||||||
| Kleweno et al.[ | Short | NI | NI | 80 (36.5%) | 0.930 | 7 (3.20%) | 0.810 | 6 (2.70%) | 0.35 | NI | NI | NI | NI |
| Long | NI | 122 (35.9%) | 12 (3.50%) | 5 (1.50%) | NI | NI | |||||||
| Hou et al.[ | Short | 22 (22.0%) | 0.785 | 10 (10.0%) | 0.518 | 5 (5.0%) | 0.809 | 0 (0.00%) | 0.178 | 1 (1.00%) | 0.942 | NI | NI |
| Long | 42 (23.0%) | 23 (12.6%) | 8 (4.4%) | 2 (1.10%) | 2 (1.10%) | NI | |||||||
| Frisch et al.[ | Short | NI | NI | NI | NI | NI | NI | 6 (8.30%) | 0.013* | 1 (1.40%) | 0.637 | NI | NI |
| Long | NI | NI | NI | 0 (0.00%) | 3 (3.10) | NI | |||||||
| Vaughn et al.[ | Short | NI | NI | 4 (6.63%) | NI | NI | NI | 2 (3.33%) | NI | NI | NI | NI | NI |
| Long | NI | 9 (4.60%) | NI | 0 (0.00%) | NI | NI | |||||||
| Boone et al.[ | Short | NI | NI | NI | NI | NI | NI | 1 (0.84%) | NI | NI | NI | NI | NI |
| Long | NI | NI | NI | 0 (0.00%) | NI | NI | |||||||
| Guo et al.[ | Short | NI | NI | 3 | > 0.05 | NI | NI | 1 (0.90%) | NI | 1 (0.90%) | > 0.05 | NI | NI |
| Long | NI | 4 | NI | 1 (1.30%) | 1 (1.30%) | NI | |||||||
| Sellan et al.[ | Short | 11 (15.5%) | 0.783 | 39 | NI | NI | NI | 5 (7.00%) | 0.35 | NI | NI | NI | NI |
| Long | 5 (12.8%) | 27 | NI | 1 (2.60%) | NI | NI | |||||||
| Okcu et al.[ | Short | 3 (16.6%) | 0.9 | 3 (20.0%) | 0.390 | 0 | 0.410 | NI | NI | NI | NI | 74 (8) | 0.11 |
| Long | 5 (18.1%) | 6 (33.3%) | 2 | NI | NI | 79 (10) | |||||||
| Hong et al.[ | Short | 2 (4.50%) | 0.625 | NI | NI | 4 (9.10%) | 0.689 | 3 (6.80%) | NI | NI | NI | NI | NI |
| Long | 0 (0.00%) | NI | 1 (5.00%) | 0 (0.00%) | NI | NI | |||||||
| Sadeghi et al.[ | Short | NI | NI | NI | NI | 46 (1.90%) | NI | 14 (0.60%) | NI | 1 (2.20%) | NI | NI | NI |
| Long | NI | NI | 50 (1.60%) | 13 (0.40%) | 0 (0.00%) | NI | |||||||
| Li et al.[ | Short | NI | NI | 3 (3.00%) | < 0.05* | NI | NI | NI | NI | NI | NI | 76.16 (10.84) | 0.28 |
| Long | NI | 0 (0.00%) | NI | NI | NI | 79.98 (8.9) | |||||||
| Raval et al.[ | Short | 3 (7.50%) | 0.456 | NI | NI | 1 (2.50%) | 0.556 | NI | NI | NI | NI | NI | NI |
| Long | 5 (12.50%) | NI | 2 (5.00%) | NI | NI | NI | |||||||
| Bovbjerg et al.[ | Short | NI | NI | 5 (5.25%) | NI | NI | NI | 1 (1.05%) | NI | 0 (0.00%) | NI | NI | NI |
| Long | NI | 7 (5.80%) | NI | 1 (0.83%) | 0 (0.00%) | NI | |||||||
| Shannon et al.[ | Short | NI | NI | 12 (15.5%) | 0.830 | 5 (6.25%) | 0.720 | 2 (2.49%) | 1 | 1 (1.25%) | 1 | 76 (3 months) (IQR 74–78) | 0.02* |
| Long | NI | 12 (13.60%) | 8 (9.09%) | 2 (2.27%) | 2 (2.27%) | 71 (3 months) (IQR 68,074) | |||||||
NI no information.
*Indicates statistically significant difference reported.
Figure 3Forest plot of mean operating times between long and short CMD groups. Green boxes represent weighted mean values of each study. The black diamond represents the overall pooled weighted mean of all included studies.
Figure 4Forest plot of mean estimated blood loss between long and short CMD groups. Green boxes represent weighted mean values of each study. The black diamond represents the overall pooled weighted mean of all included studies.
Figure 5Forest plot of mean length of stay between long and short CMD groups. Green boxes represent weighted mean values of each study. The black diamond represents the overall pooled weighted mean of all included studies.
Figure 6Forest plot of risk ratio for peri-implant fractures between long and short CMD groups. Blue boxes represent weighted mean values of each study. The black diamond represents the overall pooled weighted mean of all included studies.
Figure 7Forest plot of risk ratio for reoperation rates between long and short CMD groups. Blue boxes represent weighted mean values of each study. The black diamond represents the overall pooled weighted mean of all included studies.
Figure 8Forest plot of risk ratio for 1-year mortality rate between long and short CMD groups. Blue boxes represent weighted mean values of each study. The black diamond represents the overall pooled weighted mean of all included studies.
Summary of findings.
| Long compared to short cephalomedullary devices for fixation of extracapsular hip fractures | |||||
|---|---|---|---|---|---|
| Outcomes | № of participants (studies) | Certainty of the evidence (GRADE) | Relative effect (95% CI) | Anticipated absolute effects | |
| Risk with Short cephalomedullary devices | Risk difference with long cephalomedullary devices | ||||
| Operating Time | 7619 (12 observational studies) | ⨁⨁⨁◯ Moderatea | – | – | |
| Operating Time | 276 (2 RCTs) | ⨁⨁◯◯ Lowa,c,h | – | – | – |
| Estimated Blood Loss | 6593 (8 observational studies) | ⨁⨁◯◯ Lowa,d | – | – | Mean |
| Estimated Blood Loss | 150 (1 RCT) | ⨁⨁◯◯ Low e,h | – | The mean estimated Blood Loss was 7 | Mean 18 ml |
| Length of Stay | 6594 (8 observational studies) | ⨁⨁◯◯ Lowa,f | – | – | Mean |
| Length of Stay | 141 (2 RCTs) | ⨁⨁◯◯ Lowa,g,h | – | – | – |
| Peri-Implant Fractures | 7452 (9 observational studies) | ⨁⨁⨁◯ Moderatea | 11 per 1000 | ||
| Peri-Implant Fractures | 276 (2 RCTs) | ⨁⨁◯◯ Lowa,h | 46 per 1000 | ||
| Reoperation Rates | 6512 (6 observational studies) | ⨁⨁◯◯ Lowa,b,f | 22 per 1000 | ||
| Reoperation Rates | 168 (1 RCT) | ⨁⨁◯◯ Lowh | 63 per 1000 | ||
| 1-Year Mortality | 890 (5 observational studies) | ⨁⨁◯◯ Lowa,f | 251 per 1000 | ||
| 1-Year Mortality | 141 (2 RCTs) | ⨁⨁◯◯ Lowa,h | 163 per 1000 | ||
* | |||||
aInformation used to generate the estimated effect obtained from studies with moderate risk of bias.
bInformation used to generate the estimated effect obtained from studies with severe risk of bias.
cMean operating time was reported without statistical analysis or standard deviation provided in the studies included.
dEstimated blood loss across studies had a large variations and standard deviation values.
eEstimated blood loss was reported without statistical analysis or standard deviation provided in the study included.
fLarge amount of heterogeneity within results with results approaching the line of no effect.
gLength of Stay was reported without statistical analysis or standard deviation provided in the studies included.
hSmall number of studies included for analysis.